Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum (HOTPANTS)
NCT05343754Phase 3Terminated
- Sponsor
- Erasmus MC
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, open-label trial of oxygen in pyoderma gangrenosum (PG) (2 arms), sponsored by Erasmus MC. Primary endpoint: Wound healing time (time to wound closure) at 3 months. Started Jun 2022; status: terminated.
02
Drugs
oxygen
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT05343754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05343754.